EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality

Jelena Ivanovic, Vojin Vukovic, Predrag Miljic, Darko Antic

Annals of Hematology · 20.11.2026

DOI: 10.1007/s00277-026-07374-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 20.11.2026. Verfasst von Jelena Ivanovic und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Ministry of Science, Technological Development and Innovation

Zitieren

APA

Ivanovic, J., Vukovic, V., Miljic, P., & Antic, D. (2026). Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality. Annals of Hematology. https://doi.org/10.1007/s00277-026-07374-6

Vancouver

Ivanovic J, Vukovic V, Miljic P, Antic D. Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality. Annals of Hematology. 2026. doi:10.1007/s00277-026-07374-6

BibTeX
@article{Ivanovic2026,
  author = {Ivanovic, Jelena and Vukovic, Vojin and Miljic, Predrag and Antic, Darko},
  title = {Major bleeding during ibrutinib therapy in chronic lymphocytic leukemia: acquired von Willebrand syndrome as a coexisting hemostatic abnormality},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07374-6}
}
Kostenlos starten →